ArticleTranslational cancer research2025
Uridine-cytidine kinase 2 as a novel potential prognostic and therapeutic biomarker in gastric cancer.
Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Gastric cancer (GC) is one of the most prevalent and lethal malignancies worldwide, with its high mortality rate attributed to late diagnosis, limited prognostic stratification tools, and a lack of targeted therapeutic options. This study aimed to explore the biological functions and molecular mechanism of uridine-cytidine kinase 2 (UCK2) in GC to identify powerful diagnostic, prognostic, and therapeutic biomarkers for GC. Methods: We systematically analyzed the expression pattern of UCK2 across multiple datasets, including The Cancer Genome Atlas (TCGA) GC cohort, Gene Expression Omnibus (GEO) datasets, and a prospectively collected cohort of GC patients from Department of Gastric Surgery, Tianjin Medical University Cancer Institute and Hospital (Tianjin, China) (comprising matched tumor and normal adjacent tissues). We then examined the biological roles of UCK2 Results: The results showed that UCK2 expression was higher in the GC tissues than in the non-tumor tissues in TCGA and GEO datasets, and in the cohort of patients from our center. The high expression of UCK2 was closely correlated with more malignant features, such as an advanced pathological T (pT) stage (P=0.02), pathological N (pN) stage (P=0.03), and larger tumor size (P=0.01). The univariate and multivariate Cox regression analyses showed that UCK2 expression level was an independent prognostic factor (hazard ratio: 1.524, 95% confidence interval: 1.039-2.234, P=0.03). Functionally, UCK2 down-regulation or knockout significantly attenuated the proliferation, colony formation, and motility capacity of GC cells Conclusions: Our findings established UCK2 as a novel and clinically valuable biomarker, providing a potential tool for improving the diagnosis and prognosis evaluation of GC, and highlighted its potential as a therapeutic target for future anti-tumor strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.